IP Library Granted Patent US 7,498,341
Granted Patent B2
US 7,498,341 · App. 11/042,589 · Granted Mar 3, 2009

Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments

Assignee: Sanofi Aventis Deutschland GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,498,341
App. No.
11/042,589
Granted
Mar 3, 2009
Kind
B2
Abstract

The invention relates to heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.

Claims (46)

1. A compound of the formula I

in which the meanings are

R1 is OH or O—(C 1 -C 6 )-alkyl;

R2 is H or (C 1 -C 6 )-alkyl;

R3 is (C 1 -C 8 )-alkyl, (C 3 -C 7 )-cycloalkyl or benzyl;

X is N;

R4 is H, (C 1 -C 6 )-alkyl or O—(C 1 -C 6 )-alkyl;

R5 is H, F, Cl, Br, CF 3 or (C 1 -C 6 )-alkyl;

R6 is H;

R7 is H or (C 1 -C 6 )-alkyl;

R8 is pyridine, thiazole, pyrazine, pyrimidine or pyrrole;

and the physiologically tolerated salts thereof.

2. The compound of claim 1 wherein

R1 is OH or O—(C 1 -C 6 )-alkyl;

R2 is H;

R3 is (C 1 -C 8 )-alkyl, (C 3 -C 7 )-cycloalkyl or benzyl;

X is N;

R4 is H, (C 1 -C 8 )-alkyl or O—(C 1 -C 6 )-alkyl;

R5 is H, F, Cl, Br, CF 3 or (C 1 -C 6 )-alkyl;

R6 is H;

R7 is H;

R8 is pyridine, thiazole, pyrazine, pyrimidine or pyrrole;

and the physiologically tolerated salts thereof.

3. The compound of claim 1 wherein

R1 is OH or O—(C 1 -C 6 )-alkyl;

R2 is H;

R3 is (C 1 -C 8 )-alkyl, (C 3 -C 7 )-cycloalkyl or benzyl;

X is N;

R4 is H, (C 1 -C 6 )-alkyl or O—(C 1 -C 6 )-alkyl;

R5 is H, F, Cl, Br, CF 3 , or —(C 1 -C 6 )-alkyl;

R6 is H;

R7 is H;

R8 is pyridine, thiazole, pyrazine, pyrimidine or pyrrole;

and the physiologically tolerated salts thereof.

4. The compound of claim 1 wherein

R1 is OH, O—(C 1 -C 6 )-alkyl;

R2 is H;

R3 is (C 1 -C 8 )-alkyl, (C 3 -C 7 )-cycloalkyl or benzyl;

X is N;

R4 is H, (C 1 -C 6 )-alkyl or O—(C 1 -C 6 )-alkyl;

R5 is H, F, Cl, Br, CF 3 , or (C 1 -C 6 )-alkyl;

R6 is H;

R7 is H;

R8 is pyridine, thiazole, pyrazine, pyrimidine or pyrrole;

and the physiologically tolerated salts thereof.

5. A pharmaceutical composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF NAME Recorded Nov 18, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016793/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2005
From: DEFOSSA, DR. ELISABETH; KADEREIT, DR. DIETER; RUF, DR. SVEN; KLABUNDE, DR. THOMAS; SCHMOLL, DR. DIETER; HERLING, DR. ANDREAS; WENDT, DR. KARL-ULRICH
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 016024/0663 →
Priority Claims (1)
DE 10 2004 004 972 · Jan 31, 2004 · national
Continuity (2)
Provisional Application 6058241600 · Jun 24, 2004
Related Publication 20050182086A1 · Aug 18, 2005